CN103919878A - Medicine for treating fatty liver and hyperlipidaemia and preparation process thereof - Google Patents
Medicine for treating fatty liver and hyperlipidaemia and preparation process thereof Download PDFInfo
- Publication number
- CN103919878A CN103919878A CN201410181528.3A CN201410181528A CN103919878A CN 103919878 A CN103919878 A CN 103919878A CN 201410181528 A CN201410181528 A CN 201410181528A CN 103919878 A CN103919878 A CN 103919878A
- Authority
- CN
- China
- Prior art keywords
- medicine
- liver
- group
- fatty liver
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine for treating fatty liver and hyperlipidaemia and a preparation process thereof. The medicine preparation is prepared from ginseng, silybum marianum, salvia miltiorrhiza and hawthorn by the scientific preparation process and can be used for treating fatty liver diseases. The medicine is characterized in that the pure traditional Chinese medicines are selected and prepared into the preparation, and the medicine has the effects of tonifying heart and kidney, tonifying liver and strengthening spleen and stomach, and can adjust the functions of Qi and blood of human viscera, reinforce Qi and nourish blood, and quite spirit and stabilize mind, aiming at realizing the health function of improving sleeping with the coordination of a plurality of links. The medicine has the advantages of being small in toxic and side effects, treating both symptoms and root causes, and being obvious in treatment effect, fast to remove clinical symptoms, and no relapse after curing.
Description
Technical field
The present invention discloses a kind of medicine and preparation technology thereof who treats fatty liver and hyperlipemia, for diseases such as prophylactic treatment fatty liver and hyperlipemias, relates to traditional Chinese medical science pharmaceutical technology field.
Background technology
Fatty liver is a common clinical picture, comprises the pathological changes such as steatosis, the sclerosis of fatty hepatitis regulating liver-QI.The lighter is asymptomatic in fatty liver clinical manifestation, and the severe one state of an illness is violent.Generally speaking, fatty liver belongs to reversibility disease, early diagnosis for the timely Comprehensive Treatment of the cause of disease, and in liver, pathological changes still can be reversed before further developing into liver cirrhosis.The positive serious threat compatriots' of fatty liver disease health, becomes the second largest hepatopathy that is only second to viral hepatitis, has been acknowledged as the common cause of disguised liver cirrhosis.Generally speaking, fatty liver belongs to reversibility disease, and early diagnosis treatment in time often can recover normal.Lipid metabolic disorder during hyperlipemia is the main hazard factor that causes atherosclerosis (AS), and main manifestations has serum part lipid content to increase, and blood viscosity increases, and the enhancing of secondary lipid peroxidation, activities of antioxidant enzymes reduction etc.In blood plasma, lipid can not individualism, need be combined into lipoprotein with apolipoprotein and betransported.Lipoprotein mainly contains HDL-c, LDL-c.Now confirmed that serum TC, TG and LDL-c level and AS formation are proportionate, the formation of HDL-c and AS is negative correlation, and the lipid peroxidation of free radical and initiation thereof and the pathological process of AS are closely related.Therefore, if a kind of medicine can improve the direct or secondary lesion of hyperlipemia to body, as improve HDL-c content, reduce generation and development that TC, LDL-c content and TC/HDL-c, LDL-c/HDL-c ratio and the generation of minimizing lipid peroxidation product etc. all can prevent AS.
China is the country occurred frequently of fatty liver and hyperlipemia at present, and most patients work capacity and viability are had a strong impact on.But the medicine kind for fatty liver and hyperlipemia disease is numerous and diverse, and medicine prescription is wide in range, and active ingredient is indefinite, and on the high side.
Summary of the invention
The present invention proposes a kind of medicine for the treatment of fatty liver and hyperlipemia, can effectively treat the Chinese medicine composition of fatty liver and hyperlipemia disease, and component is simple, effective.
The preparation technology who the invention also discloses treatment fatty liver and hyperlipidemia, is applicable to suitability for industrialized production.
A kind of medicine for the treatment of fatty liver and hyperlipemia provided by the invention, by following raw materials by weight portion than making:
Radix Ginseng 450 ~ 550, Herba Silybi mariani 450 ~ 550, Radix Salviae Miltiorrhizae 550 ~ 800, Fructus Crataegi 800 ~ 1000.
Its optimum ratio of medicine of described treatment fatty liver and hyperlipemia is:
960 parts of Radix Ginsengs 480, Herba Silybi mariani 480, Radix Salviae Miltiorrhizae 720, Fructus Crataegi.
A kind of preparation technology who treats the medicine of fatty liver and hyperlipemia disclosed by the invention, comprises the following steps:
1) take in proportion described medicine;
2) in Radix Salviae Miltiorrhizae, Herba Silybi mariani, add 4～10 times of amount 30%～80% alcohol reflux, filter, repeat 2 times, each 0.5～3 hour, merge extractive liquid,, filtrate recycling ethanol, concentrated, dry, pulverize into fine powder, standby;
3) Radix Salviae Miltiorrhizae, Herba Silybi mariani are extracted to remaining medicinal residues and Radix Ginseng, Fructus Crataegi and after mixing, add 4～10 times of water gagings decoctions, repeat 3 times, be 0.5～3 hour at every turn, merge decoction liquor, filtrate is concentrated into relative density 1.00 ~ 1.25, slowly adds ethanol to make to reach 50% ~ 80%, standing 24 hours containing alcohol amount, filter, filtrate recycling ethanol, concentrated, drying under reduced pressure, be ground into fine powder, standby; Decocting condition is for decocting;
4) by step 2) and the spares mix homogeneously that obtains of step 3) and get final product.
Medicine of the present invention can take Chinese medicine preparation conventional method to be prepared into any conventional oral formulations.
The present invention, according to the combination principle of " monarch, minister, help, make ", makes to be required to be mutually use between each medicine, jointly brings into play therapeutical effect.Wherein, in side, Radix Ginseng is monarch, sweet temperature QI invigorating, and invigorating the spleen and regulating the stomach, as a means of the source day after tomorrow, to fill qi-blood-body fluid, reaches the object of nourishing liver, makes liver spleen close tune, promotes hepatopathy to recover.Hepatopathy with the passing of time, do not go by stasis blocking, and fresh blood is raw, and liver loses in the soft the liver failing to maintain the normal flow of QI of supporting, and minister, with Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, is dredged liver network, eliminating blood stasis to promote regeneration of blood.Herba Silybi mariani heat-clearing and toxic substances removing, dredging collateral nourishing the liver, is adjuvant drug.Fructus Crataegi blood circulation promoting and blood stasis dispelling, removing food stagnancy blood fat reducing, for making medicine.Four medicine compatibilities, the merit of playing altogether invigorating the spleen and benefiting QI, promoting blood circulation and detoxication, fat-reducing liver-protecting.
good effect of the present invention is:
Select pure Chinese herbal medicine to make preparation, pure Chinese medicines of 4 taste such as Radix Ginseng and Herba Silybi marianis, consist of, its effect is the liver soothing and the spleen invigorating, hard masses softening and resolving, the QI invigorating that nourishes blood, heat-clearing and toxic substances removing.For Alcoholic, non-alcoholic fatty liver disease and experimental hyperlipidemia, all there is preventive and therapeutic effect, can obviously alleviate the lipidosis of liver, prevent that steatosis and inflammation from occurring, and improves serum and liver lipid metabolic disorder.
The present invention proposes a kind of medicine for the treatment of fatty liver and hyperlipemia, can effectively treat the Chinese medicine composition of fatty liver and hyperlipemia disease, and component is simple, effective.
The preparation technology who the invention also discloses treatment fatty liver and hyperlipidemia, is applicable to suitability for industrialized production.
Accompanying drawing explanation
Fig. 1 is that test example 1 rat liver is organized the blank group of HE dyeing (200 *) pathology photo;
Fig. 2 is that test example 1 rat liver is organized HE dyeing (200 *) pathology photo model group;
Fig. 3 is that test example 1 rat liver is organized HE dyeing (200 *) pathology photo low dose group;
Fig. 4 is that test example 1 rat liver is organized dosage group in HE dyeing (200 *) pathology photo;
Fig. 5 is that test example 1 rat liver is organized HE dyeing (200 *) pathology photo high dose group;
Fig. 6 is that test example 1 rat liver is organized HE dyeing (200 *) pathology photo positive drug group;
Fig. 7 is that test example 2 rat livers are organized the blank group of HE dyeing (200 *) pathology photo;
Fig. 8 is that test example 2 rat livers are organized HE dyeing (200 *) pathology photo model group;
Fig. 9 is that test example 2 rat livers are organized HE dyeing (200 *) pathology photo low dose group;
Figure 10 is that test example 2 rat livers are organized dosage group in HE dyeing (200 *) pathology photo;
Figure 11 is that test example 2 rat livers are organized HE dyeing (200 *) pathology photo high dose group;
Figure 12 is that test example 2 rat livers are organized HE dyeing (200 *) pathology photo positive drug group;
Figure 13 is that test example 3 rat livers are organized the blank group of HE dyeing (200 *) pathology photo;
Figure 14 is that test example 3 rat livers are organized HE dyeing (200 *) pathology photo model group;
Figure 15 is that test example 3 rat livers are organized HE dyeing (200 *) pathology photo low dose group;
Figure 16 is that test example 3 rat livers are organized dosage group in HE dyeing (200 *) pathology photo;
Figure 17 is that test example 3 rat livers are organized HE dyeing (200 *) pathology photo high dose group;
Figure 18 is that test example 3 rat livers are organized HE dyeing (200 *) pathology photo positive drug group.
The specific embodiment
By following examples, the present invention is further described for example, and do not limit the present invention in any way, any change that those of ordinary skills made for the present invention easily realize or change do not deviating under the prerequisite of technical solution of the present invention, within all will fall into claim scope of the present invention.
embodiment 1: the preparation of capsule
Take Radix Ginseng 550g, Herba Silybi mariani 550g, Radix Salviae Miltiorrhizae 800g, Fructus Crataegi 1000g, above four tastes, Radix Salviae Miltiorrhizae, Herba Silybi mariani add 8 times of amount 75% alcohol reflux 2 times, and each 1 hour, filter, filtrate recycling ethanol, concentrated; Medicinal residues and Radix Ginseng, Fructus Crataegi merge, and add 8 times of water gagings, decoct 3 times, and each 1.5 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.15(80 ℃), add ethanol and make to reach 60% containing alcohol amount, fully stir standing 24 hours, filter, filtrate recycling ethanol, concentrated, drying under reduced pressure, pulverizes.Above-mentioned two kinds of medicated powder are mixed, be distributed into capsule, make 1000, obtain.
embodiment 2: the preparation of tablet
Take Radix Ginseng 450g, Herba Silybi mariani 450g, Radix Salviae Miltiorrhizae 550g, Fructus Crataegi 800g, above four tastes, Radix Salviae Miltiorrhizae, Herba Silybi mariani add 5 times of amount 65% alcohol reflux 2 times, and each 1 hour, filter, filtrate recycling ethanol, concentrated; Medicinal residues and Radix Ginseng, Fructus Crataegi merge, and add 10 times of water gagings, decoct 3 times, and each 1.5 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.10(80 ℃), add ethanol and make to reach 70% containing alcohol amount, fully stir standing 24 hours, filter, filtrate recycling ethanol, concentrated, drying under reduced pressure, pulverizes.Above-mentioned two kinds of medicated powder are added to starch, mix, granulate, compacting in flakes, obtains.
embodiment 3: the preparation of granule
Take Radix Ginseng 480g, Herba Silybi mariani 480g, Radix Salviae Miltiorrhizae 720g, Fructus Crataegi 960g, above 4 tastes, Radix Salviae Miltiorrhizae, Herba Silybi mariani add 6 times of amount 75% alcohol reflux 2 times, and each 1.5 hours, filter, filtrate recycling ethanol, concentrated; Medicinal residues and Radix Ginseng, Fructus Crataegi merge, and add 6 times of water gagings, decoct 3 times, and each 1 hour, collecting decoction, filter, filtrate is concentrated into relative density 1.10(80 ℃), add ethanol and make to reach 70% containing alcohol amount, fully stir standing 24 hours, filter, filtrate recycling ethanol, concentrated, drying under reduced pressure, pulverizes.Above-mentioned two kinds of medicated powder are mixed, add dextrin, granulation agent.
embodiment 4: the preparation of drop pill
Take Radix Ginseng 500g, Herba Silybi mariani 500g, Radix Salviae Miltiorrhizae 800g, Fructus Crataegi 800g, above 4 tastes, Radix Salviae Miltiorrhizae, Herba Silybi mariani add 10 times of amount 80% alcohol reflux 2 times, and each 2 hours, filter, filtrate recycling ethanol, concentrated; Medicinal residues and Radix Ginseng, Fructus Crataegi merge, and add 10 times of water gagings, decoct 3 times, and each 1.5 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.10(80 ℃), add ethanol and make to reach 60% containing alcohol amount, fully stir standing 24 hours, filter, filtrate recycling ethanol, concentrated, drying under reduced pressure, pulverizes.Above-mentioned two kinds of medicated powder are mixed, add 1.5 times of amount Polyethylene Glycol heating hot melts, mix, dripping becomes ball, obtains.
embodiment 5: the preparation of oral liquid
Take Radix Ginseng 450g, Herba Silybi mariani 500g, Radix Salviae Miltiorrhizae 720g, Fructus Crataegi 850g, above 4 tastes, Radix Salviae Miltiorrhizae, Herba Silybi mariani add 8 times of amount 65% alcohol reflux 2 times, and each 1 hour, filter, filtrate recycling ethanol, concentrated; Medicinal residues and Radix Ginseng, Fructus Crataegi merge, and add 6 times of water gagings, decoct 3 times, and each 1 hour, collecting decoction, filter, filtrate is concentrated into relative density 1.15(80 ℃), add ethanol and make to reach 65% containing alcohol amount, fully stir standing 24 hours, filter, filtrate recycling ethanol, concentrated, drying under reduced pressure, pulverizes.Above-mentioned two kinds of medicated powder are mixed, add 0.01 times of amount sweetener, add water-solubleization and make oral liquid, obtain.
below test shows the medical effect of medicine of the present invention to fatty liver and hyperlipemia:
one, the present invention is to the therapeutical effect of alcoholic fatty liver (AFLD) and Mechanism Study (test example 1)
1.1 laboratory animal
Wistar rat, male, body weight 180～220g, the quality certification number: SCXK-(Ji) 2007-0003, by preclinical medicine institute of Jilin University zoopery central supply.
1.2 medicines and reagent
Medicine of the present invention, brown ceramic powder, adopts 0.5%CMC-Na to be made into brown solution, free from extraneous odour.This product is by asking in vain
Grace medical university provides.
Silybin Capsules, adopts 0.5%CMC-Na to be configured to 0.8% silibinin solution, and this product is by sky, Tianjin
Shi Li Pharmacy stock Co., Ltd produces, lot number: 20120721.
1.3 modeling methods and observation index
Modeling method: 100 of male Wistar rats, body weight 180-220g, adaptability was fed after 1 week, according to body weight, divide 6 groups at random: medicine (1g/kg, 2g/kg, the 4g/kg) group of blank group, model group, the embodiment of the present invention 1 ~ embodiment 3 preparations, silibinin (80mg/kg) group, except blank group, all the other rats are with 40% wine 8g/Kg, and minute three gavages give (i.e. the each about 0.85ml/100g body weight of 40% wine); Within the 5th week, start to increase to 50% wine 9g/Kg, minute three gavages give (i.e. the each 0.75ml/100g body weight of 50% wine); Put to death 4 rats 8 every group of weekend, survey TC, TG, LDL-c, HDL-c, observe AFLD and whether set up.As model, set up, since the 9th week gavage of dividing into groups, give relative medicine, model and blank group give the sodium carboxymethyl cellulose of same volume 0.5%.Within the 9th week, start wine and increase to 10g/Kg, minute three gavages give (i.e. the each 0.85ml/100g body weight of 50% wine), and blank group gavage gives the water of same volume.With normal forage feed, also freely drink water.To 16 rat fasting at weekend 12 hours, can't help water, with chloral hydrate 30mg/kg intraperitoneal injection of anesthesia, abdominal aortic blood, serum processed; Cut open and get liver, liver homogenate processed after measurement liver index, is determined as follows index.
Observation index
1) measure liver function (ALT, AST);
2) blood fat (TC, TG, VLDL, FFA);
3) free radical (MDA, SOD);
4) perusal of liver gross specimen and measurement liver index;
5) measure hepatic tissue TC, TG and free radical (MDA, SOD);
6) light Microscopic observation (HE dyeing) steatosis and inflammation situation.
Attached: ethanol dosage (g)=ethanol volume (ml) * prewired alcohol concentration (%) * 0.8(g/ml)
1.3.1 serum TC, TG, MDA, SOD, VLDL, FFA, ALT and AST measure
Ventral aorta blood sampling, separation of serum, according to TC, TG, MDA, SOD, VLDL, FFA, ALT and AST test kit description, in each pipe, add corresponding reagent, according to preliminary experiment result, determine that sample adds volume, measure TC, TG, MDA, VLDL, FFA, ALT and AST content and SOD activity in serum.
1.3.2 the mensuration of liver index
Rat anesthesia, abdominal cavity is got blood and is put to death, and opens abdominal cavity and takes out liver, carefully removes connective tissue around, after normal saline washing, with filter paper, blots, and electronic balance weighing liver weight in wet base, calculates liver index.
Liver index=liver weight in wet base/body weight * 100%
1.3.3 the TC of liver tissue homogenate, TG, MDA and SOD measure
The preparation of the even oar of 10% hepatic tissue: get the about 1.0g of clean hepatic tissue blocking, put into small beaker.Measure the pre-cold saline of 9 times of hepatic tissue blocking weight, get wherein and 2/3 put into small beaker, with eye scissors, shred as early as possible hepatic tissue blocking.The hepatic tissue shredding is poured in homogenizer with normal saline, with after remaining 1/3 normal saline flushing small beaker, together poured into homogenizer, fully grind, be 10% liver tissue homogenate, with 3000rmp rotating speed, centrifugal, 20min, gets supernatant standby.According to TC, TG, MDA and SOD test kit description, in each pipe, add corresponding reagent, according to preliminary experiment result, determine that sample adds volume, measure the TC of liver tissue homogenate, TG, MDA content, SOD is active.
1.3.4 hepatic pathology morphological observation
Rat liver is organized HE dyeing: every group of 4 rats laterally cut the liver organization that thickness is approximately 2mm, immerse in 4% paraformaldehyde fixing, then dehydration, waxdip, paraffin embedding are prepared paraffin section, again successively through dimethylbenzene dewaxing, fall gradient ethanol aquation, haematoxylin and Yihong dyeing, rise gradient alcohol dehydration, the operation such as dimethylbenzene is transparent, neutral gum mounting, cardiac muscular tissue's section of preparation HE dyeing, in the pathological change of optical microphotograph Microscopic observation cardiac muscular tissue.
1.4 statistical method
Experimental data with means standard deviation (
± s) represent, adopt the t check of group difference comparison to carry out statistical analysis.P<0.05 thinks that difference has statistical significance.
1.5 experimental result
1.5.1 the impact of medicine of the present invention on AFLD rat lipid metabolism
Compare with blank group, model group TC, TG, VLDL and FFA content are all increased significantly, TC in liver tissue homogenate, TG content raise (
p< 0.05 or
p< 0.01), medicine 2g/kg, the 4g/kg dosage group of the embodiment of the present invention 1 ~ 3 preparation, silibinin group all can obviously reduce TC in serum, TG, VLDL and FFA content, also significantly reduction of TC, TG content in liver tissue homogenate (
p< 0.05 or
p< 0.01), in Table 1.
Table 1 medicine of the present invention on the impact of AFLD lipid metabolism in rats (
± s, n=10)
With the comparison of blank group
# p< 0.05,
## p< 0.01,
### p< 0.001; With model group comparison
* p< 0.05,
* p< 0.01
1.5.2 the impact of medicine of the present invention on AFLD rat serum liver heat removing enzyme
Compare with blank group, model group AST, ALT obviously raise (
p< 0.05 or
p< 0.01), medicine 2g/kg, 4g/kg dosage group, the silibinin group of the embodiment of the present invention 1 ~ embodiment 3 preparation all can obviously reduce serum alt content (
p< 0.05 or
p< 0.01), in Table 2.
Table 2 medicine of the present invention on the impact of AFLD rat serum liver heat removing enzyme (
± s, n=10)
| Group | Dosage g/kg | ALT（μmol/mL） | AST（μmol/mL） |
| Blank group | — | 21.24±8.40 | 61.44±20.46 |
| Model group | — | 31.75±8.99 ## | 83.51±27.21 # |
| Medicine of the present invention | 1 | 27.78±8.46 | 61.30±25.09 |
| ? | 2 | 24.19±6.43 * | 62.16±24.12 |
| ? | 4 | 20.83±7.88 ** | 63.04±22.35 |
| Silibinin | 0.08 | 23.27±6.07 * | ? ?69.85±21.15 |
With the comparison of blank group
# p< 0.05,
## p< 0.01; With model group comparison
* p< 0.05,
* p< 0.01
1.5.3 the impact of medicine of the present invention on AFLD rat oxidative metabolism
Compare with blank group, in model group serum and liver tissue homogenate MDA content be all increased significantly (
p< 0.05 or
p< 0.01), SOD activity decreased, the medicine 4g/kg dosage group of the embodiment of the present invention 1 ~ embodiment 3 preparation all can obviously reduce MDA content in hepatic tissue (
p< 0.05 or
p< 0.01), medicine 2g/kg of the present invention, 4g/kg group all can obviously reduce MDA content in serum, rising serum and SOD activities of liver (
p< 0.05), in Table 3.
Table 3 medicine of the present invention on the impact of AFLD rat oxidative metabolism (
± s, n=10)
With the comparison of blank group
# p< 0.05,
## p< 0.01; With model group comparison
* p< 0.05,
* p< 0.01
1.5.4 the impact of medicine of the present invention on AFLD rats'liver index
Compare with blank group, model group liver index obviously raise (
p< 0.001), compare with model group, the medicine 2g/kg of the embodiment of the present invention 1 ~ embodiment 3 preparation, 4g/kg group to liver index all have no significant effect (
p>0.05), in Table 4.
The impact of table 4 medicine rats'liver of the present invention index (
± s, n=10)
With the comparison of blank group
### p< 0.001
1.5.5 rat liver is organized HE dyeing (200 *) result
Blank group: hepatocyte marshalling is streak, and hepatocyte kytoplasm enriches pinkiness, the rounded cell central authorities that are positioned at of karyon, central vein, sinus hepaticus and portal area no abnormality seen, be normal liver tissue (Fig. 1).
Model group: equal visible size, quantity circular cavity not etc. in the hepatocyte of the overwhelming majority, except 1 exception, the 3 routine sinus hepaticus of remaininging are obviously expanded, and the hepatocyte at the sinus hepaticus place of expansion obviously attenuates, nucleus ovalize or crescent (Fig. 2).
Positive drug group: have the circular cavity of little, quantity 1-2 in accidental indivedual hepatocyte, except 1 exception, the 3 routine sinus hepaticus of remaininging are obviously expanded, and the hepatocyte at the sinus hepaticus place of expansion obviously attenuates, nucleus ovalize or crescent, but the face of getting involved is significantly less than model group (Fig. 3).
Low dose group: equal visible size, quantity circular cavity not etc. in the hepatocyte of the 1 example overwhelming majority, 3 examples are dispersed in the hepatocyte of fraction all circular cavitys of as seen little, quantity 1-2,4 routine sinus hepaticus are obviously expanded, the hepatocyte at the sinus hepaticus place of expansion obviously attenuates, nucleus ovalize or crescent (Fig. 4).
Middle dosage group: equal visible size, quantity circular cavity not etc. in the hepatocyte of the 1 example overwhelming majority, 3 examples are dispersed in the hepatocyte of fraction all circular cavitys of as seen little, quantity 1-2,4 routine sinus hepaticus are obviously expanded, the hepatocyte at the sinus hepaticus place of expansion obviously attenuates, nucleus ovalize or crescent (Fig. 5).
High dose group: have the circular cavity of little, quantity 1-2 in accidental indivedual hepatocyte, except 1 exception, the 3 routine sinus hepaticus of remaininging are obviously expanded, and the hepatocyte at the sinus hepaticus place of expansion obviously attenuates, nucleus ovalize or crescent, but the face of getting involved is significantly less than model group (Fig. 6).
two, medicine of the present invention is to the therapeutical effect of non-alcoholic fatty liver disease (NAFLD) and Mechanism Study (test example 2)
2.1 laboratory animal
Wistar rat, male, 100, body weight 200-240g, the quality certification number: SCXK-(Ji) 2007-0003, by preclinical medicine institute of Jilin University zoopery central supply.
2.2 medicines and reagent
Medicine of the present invention, brown ceramic powder, adopts 0.5%CMC-Na to be made into brown solution, free from extraneous odour.This product is provided by Norman Bethune Medical University.
Silybin Capsules, adopts 0.5%CMC-Na to be configured to 0.8% silibinin solution, and this product is produced by Tianjin Tasly Pharmaceutical Co., Ltd, lot number: 20120402.
2.3 experimental techniques and observation index
Preparation high lipid food
[1]: 82.5% normal feedstuff; 0.5% fish flour; 2% yolk powder; 7.5% Adeps Sus domestica; 2% cholesterol; 0.3% sodium cholate; 0.2% propylthiouracil; 5% analysis for soybean powder.
Get 100 of Wistar rats, normally feed after 1 week, by body weight, be divided at random 6 groups: normal group, model group, the embodiment of the present invention 1 ~ 3 medicine group (1,2,4g/kg) and silibinin group (80mg/kg).Except normal group is given normal forage feed, all the other each groups are all given high lipid food and are fed, and each group is freely drunk water.Modeling starts on the 5th week, and each treatment group gavage gives relative medicine, and normal group and model group give 0.5% sodium carboxymethyl cellulose of equivalent, once a day, continues 4 weeks.Weigh in once weekly.
Observation index
1) measure liver function (ALT, AST);
2) blood fat (TC, TG, LDH, HDL, VLDL, CHE, FFA, LDL);
3) liver index, fasting insulin opposing index;
4) free radical (MDA, SOD, NF-κ B, TNF-α, IL-6);
5) perusal of liver gross specimen and measurement liver index;
6) measure hepatic tissue TC, TG and free radical (MDA, SOD);
7) light Microscopic observation (HE dyeing) steatosis and inflammation situation.
2.4.1 the mensuration of serum TC, TG, MDA, SOD, VLDL, FFA, ALT, AST, LDH, CHE, LDL, HDL, NF-κ B, TNF-α and fasting insulin
Ventral aorta blood sampling, separation of serum, according to TC, TG, MDA, SOD, VLDL, FFA, ALT, AST, LDH, CHE, LDL, HDL, NF-κ B, TNF-α, IL-6 and fasting insulin test kit description, in each pipe, add corresponding reagent, according to preliminary experiment result, determine that sample adds volume, measure TC, TG, MDA, VLDL, FFA, LDL, HDL, NF-κ B, TNF-α, IL-6 content in serum, ALT, AST, LDH, CHE and SOD are active, fasting insulin level.
2.4.2 liver index and fasting insulin are resisted the mensuration of index
Rat anesthesia, abdominal cavity is got blood and is put to death, and by blood glucose meter, measures fasting glucose, opens abdominal cavity and takes out liver, carefully removes connective tissue around, after normal saline washing, with filter paper, blots, and electronic balance weighing liver weight in wet base, calculates liver index.
Liver index=liver weight in wet base/body weight * 100%
Fasting insulin opposing index=LN (fasting glucose * fasting insulin level/22.5)
2.4.3 the TC of liver tissue homogenate, TG, MDA and SOD measure
The preparation of the even oar of 10% hepatic tissue: get the about 1.0g of clean hepatic tissue blocking, put into small beaker.Measure the pre-cold saline of 9 times of hepatic tissue blocking weight, get wherein and 2/3 put into small beaker, with eye scissors, shred as early as possible hepatic tissue blocking.The hepatic tissue shredding is poured in homogenizer with normal saline, with after remaining 1/3 normal saline flushing small beaker, together poured into homogenizer, fully grind, be 10% liver tissue homogenate, with 3000rmp rotating speed, centrifugal, 20min, gets supernatant standby.According to TC, TG, MDA and SOD test kit description, in each pipe, add corresponding reagent, according to preliminary experiment result, determine that sample adds volume, measure the TC of liver tissue homogenate, TG, MDA content, SOD is active.
2.4.4 hepatic pathology morphological observation
Rat liver is organized HE dyeing: every group of 4 rats laterally cut the liver organization that thickness is approximately 2mm, immerse in 4% paraformaldehyde fixing, then dehydration, waxdip, paraffin embedding are prepared paraffin section, again successively through dimethylbenzene dewaxing, fall gradient ethanol aquation, haematoxylin and Yihong dyeing, rise gradient alcohol dehydration, the operation such as dimethylbenzene is transparent, neutral gum mounting, cardiac muscular tissue's section of preparation HE dyeing, in the pathological change of optical microphotograph Microscopic observation cardiac muscular tissue.
2.5 statistical method
Experimental data with means standard deviation (
± s) represent, adopt the t check of group difference comparison to carry out statistical analysis.P<0.05 thinks that difference has statistical significance.
2.6 experimental result
2.6.1 the impact of medicine of the present invention on NAFLD rat lipid metabolism
Compare with blank group, model group TC and TG content be all increased significantly (
p< 0.05 or
p< 0.01), HDL content obviously reduce (
p< 0.01), VLDL is not had to obvious effect, medicine 2g/kg, 4g/kg dosage group, the silibinin group of the embodiment of the present invention 1 ~ embodiment 3 preparations all can obviously reduce TG content in serum, raise HDL contents (
p< 0.05 or
p< 0.01), medicine 4g/kg group of the present invention, silibinin group all can obviously reduce TC content in serum (
p< 0.05), in Table 5,6.
Table 5 medicine of the present invention on the impact of TC, TG in liver homogenate and serum (
± s, n=10)
The impact of VLDL, HDL, LDL, FFA in table 6 drugs on serum of the present invention (
± s, n=10)
With the comparison of blank group
# p< 0.05,
## p< 0.01; With model group comparison
* p< 0.05,
* p< 0.01
2.6.2 the impact of medicine of the present invention on NAFLD Liver Function
Compare with blank group, model group ALT is active obviously to raise (
p< 0.01), to CHE, LDH and AST without obvious effect, medicine 4g/kg dosage group of the present invention and silibinin group can reduce serum ALT activities (
p< 0.05), in Table 7.
Table 7 medicine of the present invention on the impact of NAFLD Liver Function (
± s, n=10)
With the comparison of blank group
## p< 0.01; With model group comparison
* p< 0.05
2.6.3 the impact of medicine of the present invention on NAFLD rat oxygen metabolism
Compare with blank group, in model group serum and liver tissue homogenate MDA content obviously raise (
p< 0.05 or
p< 0.01), SOD activity decreased in homogenate, medicine 1g/kg dosage group of the present invention can obviously reduce MDA content in serum (
p< 0.05), medicine 2g/kg, 4g/kg dosage group, the silibinin group of the embodiment of the present invention 1 ~ embodiment 3 preparation can obviously reduce MDA content in serum and liver tissue homogenate (
p< 0.05 or
p< 0.01), medicine 4g/kg dosage group energy increased SOD activity of the present invention (
p< 0.05), in Table 8.
Table 8 medicine of the present invention on the impact of NAFLD rat oxygen metabolism (
± s, n=10)
With the comparison of blank group
# p< 0.05,
## p< 0.01; With model group comparison
* p< 0.05,
* p< 0.01
2.6.6 the impact of medicine of the present invention on the NAFLD rat inflammation factor
Compare with blank group, in model group serum NF-κ B, TNF-α and IL-6 content be all increased significantly (
p< 0.05), medicine 2g/kg of the present invention, 4g/kg dosage group all can obviously reduce NF-κ B and TNF-alpha content (
p< 0.05 or
p< 0.01), the medicine 4g/kg dosage group of the embodiment of the present invention 1 ~ embodiment 3 preparation can obviously reduce IL-6 content (
p< 0.05), silibinin group reduction NF-κ B and IL-6 content (
p< 0.05), in Table 9.
Table 9 medicine of the present invention on the impact of TC, TG, MDA and SOD in liver tissue homogenate (
± s, n=10)
| Group | Dosage (g/kg) | NF-κB（U/mL） | TNF-α（ng/mL） | IL-6（pg/mL） |
| Blank group | — | 2.65±0.86 | 0.33±0.17 | 75.63±23.60 |
| Model group | — | 4.11±0.94 # | 0.48±0.19 # | 93.07±20.45 # |
| Medicine of the present invention | 1 | 3.26±1.50 | 0.39±0.14 | 88.01±16.01 |
| ? | 2 | 3.09±0.75 * | 0.32±0.13 * | 96.87±21.09 |
| ? | 4 | 3.05±0.37 * | 0.29±0.08 ** | 80.75±9.23 * |
| Silibinin | 0.08 | 3.08±0.34 * | 0.39±0.13 | 74.81±20.55 * |
With the comparison of blank group
# p< 0.05,
## p< 0.01; With model group comparison
* p< 0.05,
* p< 0.01
2.6.7 the impact of medicine of the present invention on rats'liver exponential sum fasting insulin opposing index
Compare with blank group, model group liver index obviously raise (
p< 0.001), insulin resistance index is without significant change.Compare with model group, medicine of the present invention to liver index and insulin resistance index all have no significant effect (
p>0.05), in Table 10.
The impact of table 10 medicine rats'liver of the present invention exponential sum fasting insulin opposing index (
± s, n=10)
| Group | Dosage (g/kg) | Liver index | Insulin resistance index |
| Blank group | — | 2.52±0.15 | 1.90±0.52 |
| Model group | — | 3.00±0.42 ### | 1.61±0.58 |
| Medicine of the present invention | 1 | 3.20±0.27 | 1.68±0.37 |
| ? | 2 | 3.06±0.41 | 1.49±0.77 |
| ? | 4 | 3.17±0.40 | 1.56±0.52 |
| Silibinin | 0.08 | 2.87±0.35 | ? ?1.46±0.50 |
With the comparison of blank group
### p< 0.001
2.6.8 rat liver is organized HE dyeing (200 *) result
Normal group: liver color and luster is normal, clear-cut margin, smooth surface.Visible lobules of liver clear in structure under mirror, limiting plate is level and smooth, hepatic cords, sinus hepaticus marshalling rule.Hepatocyte endochylema is red to be dyed, and core is placed in the middle, has no the degeneration pathology such as steatosis and necrocytosis and changes.Portal area three-tube structure is clearly visible, and Non Apparent Abnormality is normal liver tissue structure (Fig. 7).
Model group: the circular cavity that the visible large smallest number of hepatocyte does not wait, hydropic degeneration, liver cell fatty degeneration (Fig. 8).
Positive drug group: be all slight hydropic degeneration and change, drip (Fig. 9) without obvious fat in hepatocyte.
High dose group: swelling of liver cell is slight hydropic degeneration and changes, drips (Figure 10) without obvious fat in hepatocyte.
Middle dosage group: swelling of liver cell is slight hydropic degeneration and changes, drips (Figure 11) without obvious fat in hepatocyte.
Low dose group: swelling of liver cell is slight hydropic degeneration and changes, drips (Figure 12) without obvious fat in hepatocyte.
three, the preventive and therapeutic effect research (test example 3) of the present invention to experimental hyperlipidemia
3.1 laboratory animal
Wistar rat, male, body weight 180～220g, the quality certification number: SCXK-(Ji) 2007-0003, by preclinical medicine institute of Jilin University zoopery central supply.
3.2 medicines and reagent
Medicine of the present invention, brown ceramic powder, adopts 0.5%CMC-Na to be made into brown solution, free from extraneous odour.This product is cured by Bethune
University of section provides.
Silybin Capsules, adopts 0.5%CMC-Na to be configured to 0.8% silibinin solution, and this product is by sky, Tianjin scholar's power system
Medicine limited company produces, lot number: 20120721.
2.3 modeling methods and observation index
modeling method:72 of male Wistar rats, body weight 180-220g, adaptability was fed after 1 week, according to body weight, divide 6 groups at random: blank group, model group, medicine (the 1g/kg of the embodiment of the present invention 1 ~ embodiment 3 preparations, 2g/kg, 4g/kg) group, silibinin (80mg/kg) group, except blank group, all the other rats give the high lipid food (formula of high lipid food: 1% cholesterol in 6:00～7:00 every night, 0.2% propylthiouracil, 0.5% sodium cholate, 2% Adeps Sus domestica, 5% Semen Glycines, 0.5% Ovum Gallus domesticus album, 0.5% fish flour, 2% yolk powder, 88.3% normal feedstuff), every average 20g of Mus, supplement enough normal diets daytime, normal feedwater.Blank group gives normal diet every day.From modeling, every morning 8:00～9:00 gives high fat group rat oral gavage administration 1 time, and blank group and model control group, to same volume 0.5% sodium carboxymethyl cellulose, once a day, continue 4 weeks.After last administration, rat fasting is 12 hours, can't help water.With chloral hydrate 30mg/kg intraperitoneal injection of anesthesia, abdominal aortic blood, prepares serum; Cut open and get liver, send pathology to carry out Histomorphological.
observation index and assay method:
1. get blood 2ml, standing separation serum, measures TG content by GPO-PAP method; Use PTA-Mg
2+precipitation Determination HDL-c content; With PVS Precipitation Determination LDL-c content; By CHOD-PAP method, measure TC content.
2. the mensuration of protein content in organizing: have-NH of protein molecule
3 +group, when henna CBBG250 developer adds in protein standard liquid or sample, the anion on CBBG250 dyestuff and albumen-NH
3 +in conjunction with, make solution become blueness, by measuring absorbance, according to formula, calculate protein content.
3. serum and hepatic tissue MDA assay: the MDA in lipid peroxide catabolite can with thiobarbituricacidα-(TBA) condensation, form red product, at 532nm place, have maximum absworption peak.Computing formula is as follows:
4. serum regulating liver-QI tissue SOD determination of activity: produce ultra-oxygen anion free radical (O by xanthine and xanthine oxidase response system
2-), the latter is oxidized azanol and forms nitrite, under the effect of developer, presents aubergine, with visible spectrophotometer, surveys its absorbance.While containing SOD in sample, ultra-oxygen anion free radical is had to narrow spectrum inhibitory action, the nitrite forming is reduced, during colorimetric, measure the absorbance of pipe lower than the absorbance of control tube, by formula, calculate the SOD vigor that can obtain in sample.Computing formula is as follows:
5. the mensuration of PGI2 and TXA2: take the isolated blood plasma of EDTANa2 anticoagulant, adopt PLA General Hospital Science and Technology Development Center to put to exempt from provided 6-Keto-PGF1 α and TXB2 radioimmunological kit is measured the content of 6-Keto-PGF1 α and TXB2 by its description.
6. get the same position of each Mus liver and put in 10% formalin fixingly, carry out pathological study.
3.4 statistical method
Experimental data with means standard deviation (
± s) represent, adopt the t check of group difference comparison to carry out statistical analysis.P<0.05 thinks that difference has statistical significance.
3.5 experimental result
3.5.1 the impact of medicine of the present invention on hyperlipidemia rats blood lipid metabolism
Compare with blank group, high fat matched group serum TC, TG, LDL-c, TC/HDL-c and LDL-c/HDL-c all significantly raise, significantly decline of HDL-c (
p< 0.05 or
p< 0.01), show that hyperlipidemia model copies successfully.With the comparison of high fat matched group, medicine 2g/kg, 4g/kg dosage group and the silibinin group of the embodiment of the present invention 1 ~ embodiment 3 preparations all can obviously reduce serum TC, TG, LDL-c, TC/HDL-c and LDL-c/HDL-c, and the serum hdl-c(that obviously raises
p< 0.05 or
p< 0.01).Medicine 1g/kg group of the present invention has no significant effect hyperlipidemia rats blood lipid metabolism, in Table 11.
Table 11 medicine of the present invention on the impact of hyperlipidemia rats blood lipid metabolism (
± s, n=10)
With the comparison of blank group
# p< 0.05,
## p< 0.01; Compare * with model group
p< 0.05, * *
p< 0.01
3.5.2 the impact of medicine of the present invention on hyperlipidemia rats serum and liver MDA and SOD
Compare with blank group, high fat matched group serum liver MDA content obviously raises, and the active obviously reduction of SOD (
p< 0.05 or
p< 0.01), show that hyperlipidemia rat is with free radical lipid peroxidation injury.With the comparison of high fat matched group, medicine 2g/kg, 4g/kg dosage group and the silibinin group of the embodiment of the present invention 1 ~ embodiment 3 preparations all can make hyperlipidemia rats serum and liver MDA content obviously reduce, SOD is active obviously to raise (
p< 0.05 or
p< 0.01).Medicine 1g/kg group of the present invention all has no significant effect hyperlipidemia rats serum and liver MDA and SOD, in Table 12.
Table 12 medicine of the present invention on the impact of hyperlipidemia rats serum and liver MDA and SOD (
± s, n=10)
With the comparison of blank group
# p< 0.05,
## p< 0.01; Compare * with model group
p< 0.05, * *
p< 0.01
3.5.3 medicine of the present invention is to hyperlipidemia rats blood plasma PGI
2and TXA
2the impact of level
Compare high fat matched group blood plasma TXA with blank group
2level obviously increases, PGI
2level and PGI
2/ TXA
2all obviously reductions of ratio (
p< 0.01), show that hyperlipidemia rat can produce TXA
2with PGI
2dysequilibrium.With the comparison of high fat matched group, medicine 1 g/kg, 2g/kg, the 4g/kg dosage group of the embodiment of the present invention 1 ~ embodiment 3 preparations, silibinin group all can obviously increase blood plasma PGI
2level, reduces blood plasma TXA
2level, and obviously improve PGI
2/ TXA
2ratio (
p< 0.05 or
p< 0.01), in Table 13.
Table 13 medicine of the present invention is to hyperlipidemia rats blood plasma PGI
2and TXA
2the impact of level (
± s, n=10)
With the comparison of blank group
# p< 0.05,
## p< 0.01; With model group comparison
* p< 0.05,
* p< 0.01
3.5.4 the impact of medicine of the present invention on hyperlipidemia rats hepatic tissue lipidosis
Each organizes the rear row fat stains of the fixing section of liver specimens, observes hepatic tissue lipidosis situation.Result shows, 10 rat hepatocytes of blank group are showed no steatosis (0/10), 10 rat hepatocytes of high fat matched group are visible steatosis (10/10) all, medicine 1g/kg of the present invention, 2g/kg, 4g/kg dosage group and silibinin group rat hepatocytes steatosis are respectively 5/10,4/10,2/10,4/10, and fat vacuole obviously reduces.Through X
2check, medicine 2g/kg of the present invention, 4g/kg dosage group and silibinin group and high fat matched group comparing difference be (p<0.05 or p<0.01) significantly, shows that medicine of the present invention can suppress the deposition of hyperlipidemia rats liver fat (Figure 13-18).
conclusion
Above-mentioned experimental result shows, medicine of the present invention all has preventive and therapeutic effect to Alcoholic, non-alcoholic fatty liver disease and experimental hyperlipidemia, can obviously alleviate the lipidosis of liver, prevent that steatosis and inflammation from occurring, reduce serum ALT activities, improve serum and liver lipid metabolic disorder, its mechanism of action may with its tune blood fat, relevant to the damage of the inflammatory factor such as free radical resisting and NF-κ B, TNF-α and IL-6.
Claims (3)
1. treat a medicine for fatty liver and hyperlipemia, it is characterized in that being made by the crude drug of following weight portion:
Radix Ginseng 450 ~ 550, Herba Silybi mariani 450 ~ 550, Radix Salviae Miltiorrhizae 550 ~ 800, Fructus Crataegi 800 ~ 1000.
2. the medicine for the treatment of fatty liver according to claim 1 and hyperlipidemia, its optimum ratio is:
960 parts of Radix Ginsengs 480, Herba Silybi mariani 480, Radix Salviae Miltiorrhizae 720, Fructus Crataegi.
3. the preparation method of the medicine for the treatment of fatty liver according to claim 1 and 2 and hyperlipidemia, comprises the following steps:
1) take in proportion described medicine;
2) in Radix Salviae Miltiorrhizae, Herba Silybi mariani, add 4～10 times of amount 30%～80% alcohol reflux, filter, repeat 2 times, each 0.5～3 hour, merge extractive liquid,, filtrate recycling ethanol, concentrated, dry, pulverize into fine powder, standby;
3) Radix Salviae Miltiorrhizae, Herba Silybi mariani are extracted to remaining medicinal residues and Radix Ginseng, Fructus Crataegi and after mixing, add 4～10 times of water gagings decoctions, repeat 3 times, be 0.5～3 hour at every turn, merge decoction liquor, filtrate is concentrated into relative density 1.00 ~ 1.25, slowly adds ethanol to make to reach 50% ~ 80%, standing 24 hours containing alcohol amount, filter, filtrate recycling ethanol, concentrated, drying under reduced pressure, be ground into fine powder, standby; Decocting condition is for decocting;
4) by step 2) and the spares mix homogeneously that obtains of step 3) and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410181528.3A CN103919878B (en) | 2014-05-04 | 2014-05-04 | A kind of medicine and preparation technology thereof treating fatty liver and hyperlipemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410181528.3A CN103919878B (en) | 2014-05-04 | 2014-05-04 | A kind of medicine and preparation technology thereof treating fatty liver and hyperlipemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103919878A true CN103919878A (en) | 2014-07-16 |
| CN103919878B CN103919878B (en) | 2016-04-20 |
Family
ID=51138420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410181528.3A Active CN103919878B (en) | 2014-05-04 | 2014-05-04 | A kind of medicine and preparation technology thereof treating fatty liver and hyperlipemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103919878B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105456520A (en) * | 2015-12-29 | 2016-04-06 | 兖矿集团有限公司总医院 | Pharmaceutical formula for treating alcoholic liver disease and experimental method |
| CN109464630A (en) * | 2018-11-13 | 2019-03-15 | 广州知旺科技有限公司 | A kind of composition of liver-protecting fat-dropping and preparation method thereof |
| CN112826889A (en) * | 2021-03-04 | 2021-05-25 | 杭州市中医院 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease |
| CN115702917A (en) * | 2021-08-16 | 2023-02-17 | 常熟雷允上制药有限公司 | Application of kuhuang injection in preparing medicine for preventing and treating fatty liver |
| CN115843914A (en) * | 2022-12-10 | 2023-03-28 | 张大文 | Ginseng and silybum marianum seed oil phyllanthus emblica and hawthorn fruit tabletting candy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085071A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root and haw and its preparation |
| CN101406676A (en) * | 2008-11-28 | 2009-04-15 | 北京天科仁祥医药科技有限公司 | Soft capsule for treating fatty liver and preparation method thereof |
| CN101411785A (en) * | 2008-11-18 | 2009-04-22 | 谢龙利 | Lotus and hawthorn tea drink for reducing blood fat |
| CN103610850A (en) * | 2013-11-20 | 2014-03-05 | 黄立新 | Medicine for treating hyperlipemia |
-
2014
- 2014-05-04 CN CN201410181528.3A patent/CN103919878B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085071A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root and haw and its preparation |
| CN101411785A (en) * | 2008-11-18 | 2009-04-22 | 谢龙利 | Lotus and hawthorn tea drink for reducing blood fat |
| CN101406676A (en) * | 2008-11-28 | 2009-04-15 | 北京天科仁祥医药科技有限公司 | Soft capsule for treating fatty liver and preparation method thereof |
| CN103610850A (en) * | 2013-11-20 | 2014-03-05 | 黄立新 | Medicine for treating hyperlipemia |
Non-Patent Citations (4)
| Title |
|---|
| 刘步平等: "《秘传保健药酒配制1200方》", 31 October 2011, article "双参山楂酒", pages: 057 * |
| 周秋丽等: "《现代中药基础研究与临床》", 30 June 2012, article "水飞蓟" * |
| 尹国有: "《高脂血症中医调治150问》", 31 January 2011, article "高脂血症", pages: 31 * |
| 熊莉娟等: "《脂肪肝》", 31 July 2010, article "脂肪肝" * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105456520A (en) * | 2015-12-29 | 2016-04-06 | 兖矿集团有限公司总医院 | Pharmaceutical formula for treating alcoholic liver disease and experimental method |
| CN109464630A (en) * | 2018-11-13 | 2019-03-15 | 广州知旺科技有限公司 | A kind of composition of liver-protecting fat-dropping and preparation method thereof |
| CN112826889A (en) * | 2021-03-04 | 2021-05-25 | 杭州市中医院 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease |
| CN115702917A (en) * | 2021-08-16 | 2023-02-17 | 常熟雷允上制药有限公司 | Application of kuhuang injection in preparing medicine for preventing and treating fatty liver |
| CN115843914A (en) * | 2022-12-10 | 2023-03-28 | 张大文 | Ginseng and silybum marianum seed oil phyllanthus emblica and hawthorn fruit tabletting candy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103919878B (en) | 2016-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102139084B (en) | Chinese medicinal composition for treating fatty liver and preparation method and application thereof | |
| CN103919878B (en) | A kind of medicine and preparation technology thereof treating fatty liver and hyperlipemia | |
| CN103919854B (en) | Application of butterflybush flower and extract thereof to preparation of medicament | |
| CN1330345C (en) | Combination of Chinese traditional medicine for treating hyperlipemia, and preparation method | |
| CN111803600A (en) | Traditional Chinese medicine composition for preventing and treating non-alcoholic fatty liver disease and preparation method | |
| CN106266949A (en) | A kind of compound Chinese medicinal preparation and its preparation method and application | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN107029074A (en) | A kind of pharmaceutical composition and preparation method and purposes for treating fatty liver | |
| CN100551396C (en) | A kind of Chinese patent medicine for the treatment of fatty liver and preparation method thereof | |
| CN103877323B (en) | Medicinal composition for treating non-alcoholic fatty liver disease | |
| CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN104826049A (en) | Medicated food for preventing and treating atherosclerosis, preparation method and applications thereof | |
| CN107184831B (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| CN103223143B (en) | Traditional Chinese medicine composition for treating simple obesity, and preparation method and application thereof | |
| CN108478745A (en) | One seed ginseng Chinese herbaceous peony nourishing qi and blood particle Chinese medicine composition and preparation method thereof | |
| CN105816549A (en) | Medicine for preventing and treating atherosclerotic plaque and preparation method thereof | |
| CN102935151B (en) | Medicine composition for protecting liver and lowering transaminase and preparation method and application thereof | |
| CN116832083B (en) | Preparation process and application of traditional Chinese medicine tea beverage composition capable of preventing early glycolipid metabolic disorder | |
| CN103191224A (en) | Liver-protecting function of hedan preparation | |
| CN103239652B (en) | Pharmaceutical composition for treatment of chronic kidney disease and preparation method and application thereof | |
| WO2023025228A1 (en) | Traditional chinese medicine composition, and preparation method therefor and use thereof | |
| CN113952432A (en) | Application of three-kernel decoction in preparation of drugs for treating fatty liver | |
| CN115487260A (en) | Traditional Chinese medicine composition for treating hypercholesterolemia or atherosclerosis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 130011 No. 358 Innovation Road, Changchun High-tech Zone, Jilin Province Patentee after: Changchun Bethune Pharmaceutical Co., Ltd. Address before: 130011 No. 358 Innovation Road, Changchun High-tech Development Zone, Jilin Province Patentee before: Pharmaceutical Factory, Bethune Medical Univ. |